Fig. 3: Simulated exposures (AUC) following CAP256V2LS administration following a single dose (A1, B1) and each 24-week steady state dose (A2, B2) with and without EDP. | Nature Communications

Fig. 3: Simulated exposures (AUC) following CAP256V2LS administration following a single dose (A1, B1) and each 24-week steady state dose (A2, B2) with and without EDP.

From: Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected women

Fig. 3

Median values (and 95% CI) of 1000 simulated replicates from the pharmacokinetic model are presented. The model was based on the results from the complete CAPRISA 012B trial6. In each case, groups with EDP have higher exposure. The model is based on simulated data derived from HIV-uninfected participants who received CAP256V2LS alone or in combination and have completed follow-up to date.

Back to article page